Accendra Health, Inc. (ACH)
| Market Cap | 222.86M -58.6% |
| Revenue (ttm) | 2.72B -0.0% |
| Net Income | -1.08B |
| EPS | -14.11 |
| Shares Out | 76.58M |
| PE Ratio | n/a |
| Forward PE | 5.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 818,638 |
| Open | 2.970 |
| Previous Close | 3.040 |
| Day's Range | 2.900 - 3.175 |
| 52-Week Range | 1.840 - 9.550 |
| Beta | 1.70 |
| Analysts | Buy |
| Price Target | 4.56 (+56.7%) |
| Earnings Date | May 11, 2026 |
About ACH
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines includi... [Read more]
Financial Performance
In 2025, Accendra Health's revenue was $2.76 billion, an increase of 3.06% compared to the previous year's $2.68 billion. Losses were -$1.10 billion, 203.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ACH stock is "Buy." The 12-month stock price target is $4.56, which is an increase of 56.70% from the latest price.
News
Accendra Health Transcript: AGM 2026
The meeting approved all four proposals, including director elections and incentive plan. The company highlighted its transition to a pure play home-based care provider, serving most of the U.S. with a streamlined workforce and strong brand presence.
Accendra Health price target raised to $4.50 from $3 at UBS
UBS raised the firm’s price target on Accendra Health (ACH) to $4.50 from $3 and keeps a Neutral rating on the shares.
Accendra Health price target raised to $6 from $5 at Baird
Baird raised the firm’s price target on Accendra Health (ACH) to $6 from $5 and keeps an Outperform rating on the shares.
Accendra Health price target raised to $5 from $3.25 at Citi
Citi raised the firm’s price target on Accendra Health (ACH) to $5 from $3.25 and keeps a Buy rating on the shares.
Accendra Health Earnings Call Transcript: Q1 2026
First quarter 2026 results met expectations, with revenue down 6.8% year-over-year but up 1% excluding a major payer exit. Gross margins nearly doubled post-divestiture, and a comprehensive balance sheet optimization will reduce debt and extend maturities.
Accendra Health reports Q1 EPS (4c) vs. 29c last year
Reports Q1 revenue $627.8M vs. $673.9M last year. “Our first quarter results were aligned with our expectations as we continue our transformation into a pure play home based care company.
Accendra Health backs FY26 guidance for net revenue and adjusted EBITDA
06:38 EDT Accendra Health (ACH) backs FY26 guidance for net revenue and adjusted EBITDA
Accendra Health Reports First Quarter 2026 Financial Results and Announces Comprehensive Balance Sheet Optimization Transaction
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) today reported financial results for the first quarter ended March 31, 2026, and announced a more than $1.5 billion comprehensive bala...
Accendra Health Announces First Quarter 2026 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the first quarter of 2026 on Monday, May 11, 2026, before trading begins on the...
Accendra Health price target lowered to $3.25 from $4 at Citi
Citi lowered the firm’s price target on Accendra Health (ACH) to $3.25 from $4 and keeps a Buy rating on the shares.
Accendra Health price target lowered to $3 from $4 at UBS
UBS analyst Kevin Caliendo lowered the firm’s price target on Accendra Health (ACH) to $3 from $4 and keeps a Buy rating on the shares. The firm updated the company’s…
Accendra Health Earnings Call Transcript: Q4 2025
Revenue grew over 3% in 2025 to nearly $2.8B, with strong performance in sleep, ostomy, and urology. 2026 guidance reflects a $300M revenue headwind from a major payer loss, but cost reductions and technology investments are expected to support margins and cash flow.
Accendra Health reports Q4 adjusted EPS 21c, consensus 22c
Reports Q4 revenue $709M, consensus $714.73M. “We ended the fourth quarter with the completion of the sale of the Products & Healthcare Services (P&HS) business on December 31, 2025, and…
Accendra Health sees FY26 revenue $2.55B-$2.65B, consensus $2.6B
Sees FY26 adjusted EBITDA $335M-$355M.
Accendra Health Reports Fourth Quarter 2025 Financial Results
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect th...
Accendra Health Announces Fourth Quarter 2025 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the fourth quarter of 2025 on Thursday, February 19, 2026, after trading ends o...
Accendra Health price target lowered to $4 from $7 at Citi
Citi lowered the firm’s price target on Accendra Health (ACH) to $4 from $7 and keeps a Buy rating on the shares as part of the firm’s 2026 outlook note…
Accendra Health price target lowered to $5 from $7 at Baird
Baird analyst Eric Coldwell lowered the firm’s price target on Accendra Health (ACH) to $5 from $7 and keeps an Outperform rating on the shares. The firm updated its model…
Accendra Health price target lowered to $2.50 from $4.70 at BofA
BofA lowered the firm’s price target on Accendra Health (ACH) to $2.50 from $4.70 and keeps an Underperform rating on the shares. Heading into 2026, the firm maintains its positive…
Accendra Health, Inc. to Begin Trading on NYSE under New Ticker “ACH”
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) announced that the Company's common stock will begin trading on the New York Stock Exchange under its new ticker symbo...
Owens & Minor, Inc. Completes Sale of Products & Healthcare Services Business to Platinum Equity
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) (the “Company”) announced the completion of the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to...
Owens & Minor Announces Corporate Name Change to Accendra Health, Inc.
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) (“the Company”) today announced that it will change its name to Accendra Health, Inc. with an anticipated effective date of December 31,...
Owens & Minor to Present at Upcoming Investor Conferences on December 2, 2025
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) announced today that members of its management team are scheduled to participate in two upcoming investor conferences. Citi 2025 Global ...
Accendra Health Earnings Call Transcript: Q3 2025
Announced sale of Products and Healthcare Services segment, shifting focus to higher-margin Patient Direct home-based care. Q3 revenue grew modestly, with strong performance in sleep therapy and ostomy, while guidance for 2025 was affirmed. Free cash flow and margins are expected to improve post-divestiture.
Owens & Minor Reports Third Quarter 2025 Financial Results
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the third quarter ended September 30, 2025. Unless otherwise noted, the results herein reflect the ...